Evidence map›Paper›PMID 39776537›Full record

ReviewTherapeutic advances in medical oncology2025

The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.

Barbara Melosky, Rosalyn A Juergens, Shantanu Banerji, Adrian Sacher, Paul Wheatley-Price, Stephanie Snow, Ming-Sound Tsao, Natasha B Leighl, Ilidio Martins, Parneet Cheema and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Barbara MeloskyMedical Oncology, BC Cancer Agency-Vancouver, University of British Columbia, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.ORCID https://orcid.org/0000-0003-2865-659X
Rosalyn A JuergensJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Shantanu BanerjiPaul Albrechtsen Research Institute, CancerCare Manitoba, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Adrian SacherPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Paul Wheatley-PriceOttawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Stephanie SnowQEII Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
Ming-Sound TsaoUniversity Health Network and Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-9160-5405
Natasha B LeighlPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Ilidio MartinsKaleidoscope Strategic Inc., Toronto, ON, Canada.
Parneet CheemaWilliam Osler Health System, University of Toronto, Brampton, ON, Canada.
Geoffrey LiuPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Quincy S C ChuCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.ORCID https://orcid.org/0000-0003-4814-3126

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small-cell lung cancer (NSCLC) is a highly heterogeneous disease that is frequently associated with a host of known oncogenic alterations. Advances in molecular diagnostics and drug development have facilitated the targeting of novel alterations such that the majority of NSCLC patients have driver mutations that are now clinically actionable. The goal of this review is to gain insights into clinical research and development principles by summary, analysis, and discussion of data on agents targeting known alterations in oncogene-driven, advanced NSCLC beyond those in the

Indexed as

antibody–drug conjugatesmonoclonal antibodiesnon-small-cell lung canceroncogenic alterationsprotein kinase inhibitorstargeted therapy

Identifiers

PMID39776537
PMCPMC11705342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.